Skip to main content

Table 4 Multiple reaction monitoring (MRM) transitions for quantification of the nine target compounds

From: Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial

Compound abbreviations*

Monitoring Mode

Parent (m/z)

Product (m/z)

Tube lens (V)

Collision energy (eV)

Retention times (min)

CCS

[M + H]+

285.16

270.30

99

23

6.43

CCSG

[M + H]+

447.24

285.30

98

20

4.89

FAN

[M + H]+

623.44

381.40

130

40

4.89

PAL

[M + H]+

352.23

336.30

89

29

5.44

5-O-M

[M + H]+

453.27

291.30

108

22

6.01

ONO

[M + H]+

431.25

269.30

97

17

6.00

FOR

[M + H]+

269.20

197.30

97

34

7.32

AST-IV

[M + Na]+

807.53

627.40

221

49

8.69

BER

[M + H]+

336.19

320.28

94

30

5.38

  1. *The compound abbreviations and their associated terms:
  2. AST-IV: astragaloside IV; BER: berberine; CCS: calycosin; CCSG: calycosin-7-O-β-D- glucoside; FAN: fangchinoline; FOR: formononetin; ONO: ononin; PAL: palmatine; 5-O-M: 5-O-methylvisammioside.
Back to article page

Trials

ISSN: 1745-6215